Natco Pharma Q4 FY23 Earnings Call Summary

Earnings Call Transcript can be found here

Key Takeaways from Management Presentation

Positives:

Strong Revenue Growth: NATCO has achieved a significant 37.6% growth in consolidated total revenue for the fiscal year ending March 31, 2023, compared to the previous year. This indicates a healthy expansion of the company’s business.

Profit Increase: The company’s net profit on a consolidated basis has increased substantially from INR 170 crores to INR 715.3 crores for the same period, showcasing robust financial performance.

Geographical Expansion: NATCO has demonstrated growth in key markets such as the U.S., Canada, and Brazil through its subsidiaries. This suggests successful international expansion and diversification.

Crop Health Division Potential: The Crop Health division is highlighted as having started well with strong potential for growth in the upcoming years, indicating a positive outlook for a specific segment of the business.

Turnaround in Q4: NATCO has managed to turn around its performance in the fourth quarter, achieving net revenue of INR 926.9 crores and a consolidated profit of INR 275.8 crores, compared to a loss in the same quarter of the previous year.

Key Takeaways from Q&A

1. Domestic Business Growth Expectations: The management expects the domestic business to improve in the upcoming fiscal year (FY ’24) with a projected growth of 8% to 10%. They anticipate achieving this growth through a combination of organic growth, acquisitions, and strategic opportunities. The goal is to compound the business at around 20% to 25% per year, driven by both acquisition and organic growth.
2. International Business Strategy and Expansion: The company has a multifaceted approach to increase international sales. They have subsidiaries in various countries that have contributed significantly to revenue, such as Canada and Brazil. Additionally, they are expanding into new markets like Colombia and Indonesia. The focus is on strengthening the global presence and leveraging the R&D pipeline to extend into multiple markets.
3. Revlimid Supply and Profit Share: The company has secured a supply of Revlimid, a significant drug, and has recognized some of the revenue from it. They plan to sell the remaining allocated quantity over the next few quarters, which is expected to contribute to future profits.
4. Agrochemical Business and Inventory: The agrochemical business saw a decline in inventory due to factors such as late approvals and setup delays, resulting in lower sales in the previous year. However, the management is confident in the upcoming Kharif season and expects to liquidate the inventory, potentially leading to improved performance in that segment.
5. Focus on R&D and Pipeline Strengthening: The company is strategically allocating surplus funds towards research and development (R&D) to strengthen its pipeline. They have achieved recent successes in gaining first-to-file (FTF) status for certain products and plan to target 8 to 10 FTFs in key markets like the U.S., Canada, and Brazil. This emphasis on building a robust pipeline underscores their commitment to future growth and innovation.
6. Expansion of Crop Protection Business: The company has set ambitious targets for its Crop Protection division, aiming for a substantial increase in revenue. They anticipate the division’s contribution to rise to INR150-plus crores for the year, potentially even targeting INR200 crores. This growth is driven by product launches, a full-year advantage, and a pipeline of upcoming products. The company sees Crop Protection as a key driver of future revenue.
7. Positive Outlook for Base Business: Despite previous challenges, the company maintains a positive outlook for its base business (excluding significant products like Revlimid). Management believes in the potential for this base business to regain strength and contribute positively. Efforts to strengthen subs, expand product portfolios, and improve overall performance are expected to contribute to stabilizing and potentially increasing profits in the coming years.
8. Focus on Niche Opportunities and Hard-to-Do Generics: The company’s focus on developing and launching niche, hard-to-do generic products stands out as a key strategy for growth. By investing in research and development (R&D) to create specialized products with higher barriers to entry, the company aims to achieve sustained profitability and avoid the highly competitive multi-generic market where margins are thin.
9. Long-Term Patient Approach: The CEO mentions that building a solid base business requires time and consistent growth across multiple geographies.
10. Selective Risk-Taking: By allocating resources to R&D for innovative products with substantial potential, the company is pursuing opportunities that can yield outsized returns. However, the CEO acknowledges the uncertainty in timing and success.
11. Market Dynamics and Competition: The management acknowledges that value in the generic drug business lies in delivering unique, hard-to-replicate products.
12. Revlimid Contribution and Future Outlook: The company is reluctant to provide specific details about the contribution of Revlimid to their financials due to competitive reasons. However, they have indicated that they are optimistic about its performance and future earnings growth. The company is cautious about giving future predictions and emphasizes the importance of focusing on hard-to-do generics and specialty products.
13. API Business Growth and Strategy: The API business has experienced significant growth driven by confirmed orders and new launches. The company anticipates a 15–20% growth in this segment. The growth is attributed to orders from customers for various products. The company focuses on pursuing patents aggressively and differentiates itself by not engaging in CDMO business.
14. Domestic and International Expansion Plans: The company is pursuing both domestic acquisitions and global R&D investments. They are actively looking for opportunities to expand their portfolio through acquisitions while also emphasizing investment in research and development. However, specific details about ongoing acquisition efforts are not disclosed due to competitive reasons.
15. Agri Business and Future Product Strategy: The company is committed to growing its agri business beyond its current product CTPR. They have a pipeline of 6–7 new products in the agri segment that are first-time indigenously produced. The company expects to reveal more about these products in the next 12 months and is optimistic about the opportunities in this sector.

Quarterly

4-Point Gauge

Technicals

Price Action

• +38% since results 29th May 2023
• +56% YTD
• +15% 1 Year